ScripPTC Therapeutics expects to reach blockbuster sales for its oral phenylketonuria (PKU) drug Sephience (sepiapterin), which obtained US Food and Drug Administration approval on July 28. The firm will t
ScripA week after Sarepta Therapeutics agreed to stop shipping Elevidys (delandistrogene moxeparvovec) to ambulatory Duchenne muscular dystrophy (DMD) patients at the request of the US Food and Drug Admi
Pink SheetA week after Sarepta Therapeutics agreed to stop shipping Elevidys (delandistrogene moxeparvovec) to ambulatory Duchenne muscular dystrophy (DMD) patients at the request of the US Food and Drug Admi
ScripRoche is ramping up plans for its ‘brainshuttle’ Alzheimer’s candidate trontinemab, unveiling a pivotal Phase III trial design and details of an additional study in patients at high risk of developing